Categories AlphaGraphs, Earnings, Health Care

Allergan’s stock falls after company reports loss in Q4

Allergan plc (AGN) saw its shares drop 4.2% in premarket hours on Tuesday after the company reported a GAAP net loss for the fourth quarter of 2018. Revenue and adjusted EPS came in ahead of expectations. Total revenues declined 5.7% to $4.08 billion compared to the same period last year.

The company reported a net loss of $4.2 billion, or $12.83 per share, for the quarter compared to a net income of $3.05 billion, or $8.88 per share, in the year-ago period, hurt by impairment charges of $5.4 billion. Adjusted EPS dropped 11.7% to $4.29 from last year.

Allergan fourth quarter 2018 earnings infographic
Allergan Q4 2018 Earnings Infographic

Allergan posted a decline in US Specialized Therapeutics revenues mainly due to lower RESTASIS revenue and the divestiture of the Medical Dermatology business in September. RESTASIS revenues dropped 18.8% in the quarter due to lower demand and net pricing.

BOTOX Cosmetic and JUVEDERM Collection posted revenue increases of 13% and 13.5%, respectively. Revenues in BOTOX Therapeutic grew 12.8% year-over-year. Despite the product recalls, OZURDEX saw an 11% growth in revenues. Revenues for ALLODERM, CoolSculpting and ALPHAGAN/COMBIGAN saw decreases during the quarter.

Earnings preview: Botox to drive Allergan’s growth in Q4

In US General Medicine, revenues declined 8.4% mainly due to lower revenues from NAMENDA XR and ESTRACE due to generic competition. International revenues inched up 1% helped by growth in Facial Aesthetics and BOTOX Therapeutic. The revenues in several international markets were affected by a recall of textured breast implants as well as lower OZURDEX sales due to a product recall.

Also see: Allergan plc Q4 2018 Earnings Conference Call Transcript

The company’s Board of Directors authorized a new $2 billion share repurchase program as part of its capital allocation strategy, which is expected to be deployed over the next 12 months.

For the first quarter of 2019, Allergan expects total revenues of $3.4 billion to $3.5 billion. GAAP loss per share is expected to be $0.39 to $0.20 while adjusted EPS is expected to be $3.40 to $3.60. For full-year 2019, the company expects total revenues to be $15 billion to $15.3 billion. GAAP EPS is expected to be around $1.14 while adjusted EPS is expected to be around $16.36.

 

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Does Unity Software (U) stock has more room to run?

Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a

PepsiCo (PEP): Steady snacking habits amid pandemic drive strong quarter for beverage giant

PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the

Does the virus-driven boom make Electronic Arts (EA) a good investment?

With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,

One thought on “Allergan’s stock falls after company reports loss in Q4

Leave a Reply

Your email address will not be published. Required fields are marked *

Add Comment
Loading...

Cancel
Viewing Highlight
Loading...
Highlight
Close
Top